Indication
Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).
Loading your page…
Loading your page…
Anemia;Kidney Failure, Chronic
Marketing Authorisation Holder: Astellas Pharma Europe B.V.
EMA Authorisation: 18/08/2021
INN: roxadustat
AI Drug & Interaction Analysis
Free account required
Ask Osler about Evrenzo: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.